Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thrombolysis Clear all
Terminated Phase 3 Interventional

ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

NCT00300196
View directory record Official record
Conditions
Stroke, Cerebral Ischemia, Brain Infarction
Interventions
Ancrod (Viprinex), Placebo
Biological · Drug
Lead sponsor
Neurobiological Technologies
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
39
States / cities
Chico, California • Fresno, California • La Mesa, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

NCT00894803
View directory record Official record
Conditions
Ischemic Stroke, Stroke, Brain Infarction
Interventions
Eptifibatide, rt-PA
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 85 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 1 Interventional

A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion

NCT00418483
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
Plasmin (Human) 25 mg, Plasmin (Human) 50 mg, Plasmin (Human) 75 mg, Plasmin (Human) 100 mg, Plasmin (Human) 125 mg, Plasmin (Human) 150 mg, Plasmin (Human) 175 mg
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Argatroban Stroke Treatment - A Pilot Safety Study

NCT00268762
View directory record Official record
Conditions
Ischemic Stroke
Interventions
argatroban
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2014 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Not applicable Interventional Results available

Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy

NCT01197573
View directory record Official record
Conditions
Liver Transplantation, Kidney Transplantation
Interventions
rTPA Treatment, No TPA Treatment
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 3 Interventional

Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries

NCT00115999
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 4 Interventional Results available

Assess the Penumbra System in the Treatment of Acute Stroke

NCT01429350
View directory record Official record
Conditions
Ischemic Stroke
Interventions
intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Penumbra System
Drug · Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Denver, Colorado • Gainesville, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Jul 22, 2026, 2:20 PM EDT
Recruiting Phase 2Phase 3 Interventional

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

NCT06990867
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
JX10, Placebo
Drug
Lead sponsor
Corxel Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Long Beach, California • Sacramento, California • Colorado Springs, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 1 Interventional

Low-Dose rtPA to Treat Blood Clots in Major Arm or Neck Veins

NCT00055159
View directory record Official record
Conditions
Thrombosis
Interventions
Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy

NCT01513759
View directory record Official record
Conditions
Pulmonary Embolism, Acute Pulmonary Embolism, Sub-massive Pulmonary Embolism, Massive Pulmonary Embolism, Pulmonary Thromboembolism
Interventions
recombinant tissue plasminogen activator, EKOS EkoSonic Endovascular System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
22
States / cities
Montgomery, Alabama • Modesto, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Jul 22, 2026, 2:20 PM EDT
Completed No phase listed Observational

Pulmonary Embolism Response to Fragmentation, Embolectomy, & Catheter Thrombolysis: PERFECT

NCT01097928
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Catheter directed debulking of Pulmonary Embolus
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Jul 22, 2026, 2:20 PM EDT
Withdrawn No phase listed Observational

Single Center Post-Market Study of Thrombolytic Therapy Using the Versus™ Catheter

NCT06975969
View directory record Official record
Conditions
Blood Clots, Vascular Disease, Embolism Thrombosis, Cardiovascular Diseases, Lung Diseases
Interventions
Versus™ Endovascular Pulmonary Artery Drug Delivery Catheter
Device
Lead sponsor
Liquet Medical Inc.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 22, 2026, 2:20 PM EDT
Recruiting Phase 2Phase 3 Interventional

Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial

NCT06949228
View directory record Official record
Conditions
Ischemic Stroke, Acute Disease
Interventions
tenecteplase
Drug
Lead sponsor
ProMedica Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Tenecteplase in Stroke Patients Between 4.5 and 24 Hours

NCT03785678
View directory record Official record
Conditions
THROMBOLYSIS
Interventions
Tenecteplase, Placebo
Biological · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
94
States / cities
Birmingham, Alabama • Mesa, Arizona • Anaheim, California + 74 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Jul 22, 2026, 2:20 PM EDT
Terminated Phase 1 Interventional Results available

Thrombolysis in Pediatric Stroke (TIPS)

NCT01591096
View directory record Official record
Conditions
Stroke
Interventions
Tissue plasminogen activator (Activase®)
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Jul 22, 2026, 2:20 PM EDT
Recruiting Phase 2 Interventional

Intra-Arterial Tenecteplase to Improve the Microvascular Hemodynamics After Mechanical Thrombectomy

NCT06904911
View directory record Official record
Conditions
Acute Ischemic Stroke From Large Vessel Occlusion
Interventions
intra-arterial tenecteplase administration
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 4 Interventional Results available

Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism

NCT02396758
View directory record Official record
Conditions
Pulmonary Embolism and Thrombosis
Interventions
Ekosonic® Endovascular Device ultrasonic infusion catheter, Recombinant tissue plasminogen activator
Device · Biological
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
16
States / cities
Beverly Hills, California • Tallahassee, Florida • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 2 Interventional

Interventional Management of Stroke (IMS) II Study

NCT00243906
View directory record Official record
Conditions
Stroke
Interventions
Recombinant tissue plasminogen activator, Low-intensity ultrasound
Drug · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Jul 22, 2026, 2:20 PM EDT
Completed No phase listed Observational Results available

Stroke Team Remote Evaluation Using a Digital Observation Camera

NCT00283868
View directory record Official record
Conditions
Stroke
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
4
States / cities
Brawley, California • El Centro, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Jul 22, 2026, 2:20 PM EDT
Not yet recruiting Phase 3 Interventional

Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant

NCT07621796
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Intravenous tenecteplase (TNK), Placebo
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 1 Interventional

Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke

NCT00283088
View directory record Official record
Conditions
Stroke
Interventions
hypothermia, tissue plasminogen activator
Procedure · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
7
States / cities
Palo Alto, California • San Diego, California • Hartford, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 1 Interventional

Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion

NCT01581411
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Tissue Plasminogen Activator
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Jul 22, 2026, 2:20 PM EDT
Completed No phase listed Observational

The Effect of Implementing Hyper-acute Stroke Guidelines on Decision-Making for or Against Thrombolytic Therapy for Stroke in the Emergency Department

NCT01050049
View directory record Official record
Conditions
Stroke
Interventions
Not listed
Lead sponsor
Temple University
Other
Eligibility
19 Years and older
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Jul 22, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

NCT01000727
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Darapladib 160 mg, Placebo, Standard Therapy
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
13,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
290
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 252 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Jul 22, 2026, 2:20 PM EDT